March 31, 2025
AI and Primary Immunodeficiencies: Key Takeaways from the 2nd AIPI Meeting
From March 19 to 22, leading experts came together for the 2nd AIPI Meeting, a pivotal event exploring how Artificial Intelligence (AI) can revolutionise the diagnosis, treatment, and management of Primary Immunodeficiencies (PIDs) and Inborn Errors of Immunity (IEI).
IPOPI was proud to partner in this crucial discussion, ensuring that patients’ needs remain at the heart of AI-driven innovations in rare diseases.
IPOPI’s Contributions to the AI Debate
- Martine Pergent, IPOPI President, was a key speaker, emphasizing the importance of patient-centered AI and ensuring that technological advancements align with the real-life needs of PID patients.
- Johan Prevot, IPOPI’s Executive Director, participated in discussions on AI’s potential to enhance early diagnosis, precision treatment, and patient outcomes.
- Nizar Mahlaoui, IPOPI’s Medical Advisory Panel (MAP) Chairman, contributed valuable insights on how AI can reshape clinical approaches and improve healthcare strategies for PIDs.
Key Topics Discussed
The meeting covered groundbreaking topics on AI’s role in rare diseases, including:
- Mapping patient manifestations to improve disease understanding and care pathways
- Deploying AI algorithms to accelerate and refine PID and IEI diagnoses
- Leveraging AI in epidemiology to address global health inequalities
What Comes Next? From Theory to Action
Following two days of insightful discussions, the focus now shifts to practical implementation. The challenge ahead is ensuring that AI translates into real-world benefits, improving diagnostic access and optimal care for all PID patients worldwide.
With innovation at the forefront, the future of AI in rare diseases looks promising, paving the way for earlier detection, better treatments, and improved quality of life for patients.
The journey continues toward AIPI 2025, where the next steps in AI’s integration into PID healthcare will take shape!
